surgical adjunct that can potentially reduce blood loss during resection and provide anatomical details to facilitate the surgical approach. Radiation-based therapies, including SRS, 3D-conformal radiotherapy, and intensitymodulated radiotherapy, have evolved into an important postoperative adjunct and possible alternative to microsurgery. Despite suggested efficacy of these therapies as first-line or adjunctive treatments for glomus jugulare tumors, some investigators have raised concerns that glomus jugulare tumors may be relatively radioresistant. 43 Thus, the most effective treatment modality to prevent recurrence of glomus jugulare tumors remains unclear. 43 Because of the comparative rarity of these lesions, there currently is a lack of Class I data to direct appropriate management. In this study, we assessed 869 patients with glomus jugulare tumors from the published literature to identify treatment variables that impacted clinical outcomes and tumor control rates.
Methods

Article Selection
PubMed searches were performed with key words "glomus jugulare" alone and in combination with "treatment," "morbidity," and "mortality." Inclusion criteria were the following: follow-up data for patients treated for glomus jugulare tumors were presented in a useable fashion, and articles contained disaggregated individual patient data (age, sex, treatment modality, and follow-up survival data) for each patient. After reviewing these articles, a thorough review of all referenced sources was also performed.
Our search resulted in 46 publications describing outcomes for 869 patients treated for glomus jugulare tu mors. 1, 3, 5, [7] [8] [9] [11] [12] [13] [14] [19] [20] [21] [22] [25] [26] [27] 29, 30, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] 47, 48, [50] [51] [52] [53] [54] [56] [57] [58] [61] [62] [63] [64] We then excluded articles that combined patient outcomes of glomus jugulare tumors with other histologically different jugular foramen tumors unless there was a clear distinction between the outcomes of the patients who had glomus jugulare tumors or if the articles were not available in the English-language literature. We then excluded individual patients based on the following criteria: those with a nonjugular foramen tumor location, those with inadequate data presentation, and those who received some treatment other than a combination of surgery and/or radiosurgery.
Statistical Analysis
Upon univariate comparisons of demographic information between treatment cohorts, we noted significant differences in sex distribution, age, and Fisch class 24 of tumors treated with different modalities (Table 1) . To attempt to address these potential confounders, we performed univariate comparisons on the disaggregated data available for each group to determine if age and sex independently affected recurrence rates in these patients. Using the Pearson chi-square test, we analyzed sex distribution and did not find a higher rate of recurrence between males and females (p = 0.474, chi-square test), suggesting that sex differences cannot explain between-group differences in rates of recurrence. To address the possibility that between-group differences in patient age could explain recurrence rates, we compared ages between patients who experienced recurrence and those who did not by using an independent samples t-test (after confirming normality of the data set) and found that the ages were similar between the groups (patients with recurrence 60 ± 6.5 years old vs patients without recurrence 55 ± 6.5 years old, p = 0.65). Given the inconsistency of disaggregated data presentation in the literature, we cannot address the possibility that differences in Fisch grade could confound these data; however, it should be noted that a greater number of high Fisch grade tumors were treated with radiosurgery than with GTR, which makes it unlikely that improved rates of tumor control with radiosurgery could be explained by treating simpler tumors.
After addressing possible between-group confounding variables, separate meta-analyses were performed on calculated pooled rates of recurrence and cranial neuropathy after STR, GTR, STR with adjuvant postoperative SRS, and SRS alone. New cranial neuropathies and exacerbation of existing cranial neuropathies were both defined as cranial neuropathy for purposes of analysis. Results were expressed as pooled proportions (percentages) with 95% CIs, and these values were used. Heterogeneity across the studies was evaluated using the Cochran Q statistic, and random-effects models were used to incorporate any heterogeneity present to generate a pooled proportion using methods published by DerSimonian and Laird. [15] [16] [17] [18] Individual studies were weighted using the inverse variance method, and 95% CIs for each group were calculated from the pooled proportions using the inverse Z r transform of the proportion generated from randomeffects model. [15] [16] [17] [18] Between-group hypothesis testing was performed on the calculated odds ratio of the pooled proportions. The possible effect of publication bias was assessed using funnel plots, which, upon visual inspection, did not demonstrate obvious asymmetry (data not shown). Other between-group comparisons were performed using ANOVA or the Pearson chi-square test, for continuous or categorical variables, respectively. Parametric statistics were performed only after the data were subjected to formal tests of normality. Significance was set at p < 0.05. Statistical analysis was performed using PASW version 17.0 (SPSS, Inc.).
Results
Results of the Systematic Literature Review
We identified 869 patients who met our inclusion criteria and were analyzed for this study. Gross-total resection was performed in 351 patients, STR alone was performed in 82 patients, STR+SRS was performed in 97 patients, and SRS alone was performed in 339 patients. The demographic characteristics of these patients are summarized in Table 1 . As noted in Methods, we assessed the impact of sex and patient age on rates of recurrence and did not note significant differences in either univariate analysis, suggesting that sex and age differences cannot explain differences in recurrence rates. The length of follow-up for these studies ranged from 6 to 256 months, and the mean varied by about 2 years between different 
Rates of Tumor Control After Treatment for Glomus Jugulare Tumors
We identified 46 prior studies that provided a range of follow-up for patients undergoing treatment for glomus jugulare tumors via GTR, STR, STR+SRS, and SRS alone. In each study, the tumor control rate, defined as either lack of recurrence (in patients undergoing GTR) or lack of documented growth (in those undergoing SRS and STR) was identified and analyzed. Our analysis then pooled data from these studies to find the tumor control rate in each group ( Table 2) . The tumor control rates for GTR, STR, STR+SRS, and SRS alone were 86% (95% CI 81%-91%), 69% (95% CI 57%-82%), 71% (95% CI 53%-83%), and 95% (95% CI 92%-99%), respectively. The forest plots and pooled estimate for tumor control rates in these cohorts are depicted in Fig. 1 . Comparisons of the 95% CIs for recurrence in these 4 cohorts reveal that SRS was associated with the most favorable rates of tumor control for the follow-up periods described. Grosstotal resection did not confer a significant advantage over STR or STR+SRS; however, analysis of the 95% CIs suggested that patients undergoing GTR probably do experience a small improvement in tumor control rates and that the literature is currently underpowered to detect this small difference in tumor control rates between the GTR, STR, and STR+SRS cohorts.
Cranial Nerve Morbidity After Treatment for Glomus Jugulare Tumors
Due to the differences in the data presentation between various published reports, we have a limited ability to assess nonneurological morbidity after either surgical or radiosurgical treatment. We were able to calculate the rates of new or worsened postsurgical CN neuropathy for patients treated with either GTR or SRS. Our analysis shows that with GTR, 38% (95% CI 31%-46%) of patients had a posttreatment CN IX deficit, 26% (95% CI 16%-35%) had a posttreatment CN X deficit, 40% (95% CI 32%-49%) had a CN XI posttreatment deficit, and 18% (95% CI 7%-28%) of patients had a posttreatment CN XII deficit (Table 3) .
Following SRS, 9.7% (95% CI 0%-16%) of patients had a posttreatment CN IX deficit, 9.7% (95% CI 0%-16%) had a posttreatment deficit of CN X, 12% (95% CI 6%-18%) had a posttreatment deficit of CN XI, and 8.7% (95% CI 0%-20%) of patients had a posttreatment CN XII deficit (Table 3) . Patients who underwent GTR sustained worse rates of CN deficits with regard to CNs IX-XI than those who underwent SRS; however, the rates of CN XII deficits were comparable. There were not enough data available to draw meaningful conclusions for the STR and STR+SRS cohorts.
Discussion
The treatment of patients with glomus jugulare tumors has generated interest in recent years because of the high morbidity rates associated with surgical intervention versus radiation-based treatments, including SRS.
10 This meta-analysis of the published literature suggests that the higher rates of lower CN morbidity after surgery are not associated with an increase in tumor control when compared with radiation therapy. In addition, our analysis suggests that patients undergoing GTR experience higher rates of CN deficits when than those undergoing SRS therapy. Therefore, SRS appears to provide better tumor control than surgery, with less risk, at least over the published follow-up periods seen in the existing literature. While SRS alone is appropriate for some smaller tumors, often larger tumors require an initial operation to debulk the tumor and establish a histological diagnosis, followed by SRS to achieve stasis on the more favorable radiosurgical target. Based on the published literature, this combination strategy achieves tumor control in about three-quarters of these cases, which in the absence of tumor staging data, we hypothesize comprise many aggressive and surgically complex tumors. Many observers believe that the treatment modality for glomus jugulare tumors should be dictated by the size of the tumor, and further work is needed to appropriately structure treatment recommendations in a Fisch stage-specific manner. Two studies in particular highlight the idea of appropriately size-specific management paradigms.
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Study Limitations
There are significant limitations to our study that warrant consideration, most notably related to underreporting of important variables and prognostic features. The literature does not lend itself to a useful comparison between all treatment modalities and tumor size because information such as tumor size and treatment-specific data are not universally included or uniformly represented. On a similar note, while several staging systems exist for glomus jugulare tumors, 23, 31, 49 the literature does not lend itself to any stage-specific treatment protocol because of the rarity of this entity. Previously, Springate and Weichselbaum 59 also attempted to determine the appropriate treatment modality for each stage but were ultimately unsuccessful.
By summarizing the published literature on glomus jugulare tumors, we aimed to understand the current treatment modalities available and to give an estimate of their ability to provide tumor control. However, it should be acknowledged that this review does not contain Class I or II data and should ideally be supplemented with more definitive data if and when they become available. Our analysis is limited by the quality and accuracy of these studies and may reflect source study biases, as it is impossible for us to control for the quality of the data reported in the literature. We cannot independently confirm the histological diagnosis, extent of resection, and adequacy of radiation therapy, which likely vary between studies, thereby rendering it impossible to validate these common definitions across all publications in which they are reported. Some of these limitations should be minimized with our use of meta-analysis methods, which statistically evaluate and adjust for between-study heterogeneity. Finally, due to the diverse range of data presentation, we are limited in our ability to study and control for certain variables. Potential confounders inconsistently presented across studies cannot be reviewed; however, we did address some confounders in this study (age and sex) and found that they did not influence rates of recurrence on univariate analysis. Other variables of interest, namely Fisch grade and tumor size, were not presented in a disaggregated fashion that would allow for independent assessment; however, it should be noted that higher Fisch grade tumors were more frequently found in the SRS cohort than the GTR cohort, which suggests that the data in the literature are not overly biased in favor of SRS.
Formal guidelines about the reporting of meta-analyses have been published by the MOOSE committee.
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Whenever possible, we have attempted to comply with these measures within the limitations created by the use of diverse Class III data set we are analyzing. Table 4 lists these criteria and our adherence to these reporting criteria.
Conclusions
We present a meta-analysis of patients reported on in the literature who were treated for glomus jugulare tumors, and we emphasize the importance of SRS in the treatment of these tumors. It remains to be determined whether aggressive resection of these lesions is in the best interest of the patient.
Disclosure
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Author contributions to the study and manuscript preparation include the following. Conception and design: Ivan, Aranda. Acquisition of data: Ivan, Sughrue, Kane, Aranda. Analysis and interpretation of data: Ivan, Sughrue. Drafting the article: Parsa, Ivan, Sughrue, Clark, Barani. Critically revising the article: Parsa, Ivan, Sughrue, Clark, Kane, Barani. Reviewed final version of the manuscript and approved it for submission: all authors. Statistical analysis: Ivan, Sughrue, Aranda. Study supervision: Parsa, Sughrue.
